You are not currently logged in.
Access your personal account or get JSTOR access through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Antineoplastic Bryostatins are Multipotential Stimulators of Human Hematopoietic Progenitor Cells
W. Stratford May, Saul J. Sharkis, Ahmed H. Esa, Vittorio Gebbia, Andrew S. Kraft, G. Robert Pettit and Lyle L. Sensenbrenner
Proceedings of the National Academy of Sciences of the United States of America
Vol. 84, No. 23 (Dec. 1, 1987), pp. 8483-8487
Published by: National Academy of Sciences
Stable URL: http://www.jstor.org/stable/30488
Page Count: 5
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
The bryostatins are macrocyclic lactones, extracted from the marine bryozoan Bugula neritina, and have been reported to be potent antineoplastic agents. Results described here demonstrate that the bryostatins may also be useful as stimulators of normal human hematopoietic cells since they can (i) directly stimulate bone marrow progenitor cells to form colonies in vitro and (ii) functionally activate neutrophils. Structure-activity studies with bryostatin congeners indicate that these stimulatory properties may be dependent on the chain length and the unsaturated nature of the acylated group at carbons 20 and 7 of the bryostatin molecule. These stimulatory properties demonstrate that the naturally occurring bryostatins can mimic many of the biological effects of multipotential granulocyte-macrophage colony-stimulating factor. Thus, the coupling of antineoplastic activity with stimulatory growth properties for normal hematopoietic cells makes this agent an excellent probe to dissect the mechanism(s) of normal hematopoiesis. In addition, bryostatin may represent a clinically attractive agent useful for treating bone marrow failure states.
Proceedings of the National Academy of Sciences of the United States of America © 1987 National Academy of Sciences